Trial
NCT02111096
A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Diabetes Mellitus, Type 2
Intervention
LY2409021
Why stopped
The overall benefit-risk profile did not support continued development of LY2409021 for type 2 diabetes.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-10-09